Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery.
Cardiovascular complications
Noncardiac surgery
Perioperative bleeding
Perioperative hypotension
Randomized controlled trial
Tranexamic acid
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
received:
24
09
2021
accepted:
29
12
2021
entrez:
1
2
2022
pubmed:
2
2
2022
medline:
3
2
2022
Statut:
epublish
Résumé
For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery. Although usual perioperative care is commonly consistent with a hypertension-avoidance strategy (i.e., most patients continue their antihypertensive medications throughout the perioperative period and intraoperative mean arterial pressures of 60 mmHg are commonly accepted), a hypotension-avoidance strategy may improve perioperative outcomes. The PeriOperative Ischemic Evaluation (POISE)-3 Trial is a large international randomized controlled trial designed to determine if TXA is superior to placebo for the composite outcome of life-threatening, major, and critical organ bleeding, and non-inferior to placebo for the occurrence of major arterial and venous thrombotic events, at 30 days after randomization. Using a partial factorial design, POISE-3 will additionally determine the effect of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of major cardiovascular events, at 30 days after randomization. The target sample size is 10,000 participants. Patients ≥45 years of age undergoing noncardiac surgery, with or at risk of cardiovascular and bleeding complications, are randomized to receive a TXA 1 g intravenous bolus or matching placebo at the start and at the end of surgery. Patients, health care providers, data collectors, outcome adjudicators, and investigators are blinded to the treatment allocation. Patients on ≥ 1 chronic antihypertensive medication are also randomized to either of the two blood pressure management strategies, which differ in the management of patient antihypertensive medications on the morning of surgery and on the first 2 days after surgery, and in the target mean arterial pressure during surgery. Outcome adjudicators are blinded to the blood pressure treatment allocation. Patients are followed up at 30 days and 1 year after randomization. Bleeding and hypotension in noncardiac surgery are common and have a substantial impact on patient prognosis. The POISE-3 trial will evaluate two interventions to determine their impact on bleeding, cardiovascular complications, and mortality. ClinicalTrials.gov NCT03505723. Registered on 23 April 2018.
Sections du résumé
BACKGROUND
BACKGROUND
For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery. Although usual perioperative care is commonly consistent with a hypertension-avoidance strategy (i.e., most patients continue their antihypertensive medications throughout the perioperative period and intraoperative mean arterial pressures of 60 mmHg are commonly accepted), a hypotension-avoidance strategy may improve perioperative outcomes.
METHODS
METHODS
The PeriOperative Ischemic Evaluation (POISE)-3 Trial is a large international randomized controlled trial designed to determine if TXA is superior to placebo for the composite outcome of life-threatening, major, and critical organ bleeding, and non-inferior to placebo for the occurrence of major arterial and venous thrombotic events, at 30 days after randomization. Using a partial factorial design, POISE-3 will additionally determine the effect of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of major cardiovascular events, at 30 days after randomization. The target sample size is 10,000 participants. Patients ≥45 years of age undergoing noncardiac surgery, with or at risk of cardiovascular and bleeding complications, are randomized to receive a TXA 1 g intravenous bolus or matching placebo at the start and at the end of surgery. Patients, health care providers, data collectors, outcome adjudicators, and investigators are blinded to the treatment allocation. Patients on ≥ 1 chronic antihypertensive medication are also randomized to either of the two blood pressure management strategies, which differ in the management of patient antihypertensive medications on the morning of surgery and on the first 2 days after surgery, and in the target mean arterial pressure during surgery. Outcome adjudicators are blinded to the blood pressure treatment allocation. Patients are followed up at 30 days and 1 year after randomization.
DISCUSSION
CONCLUSIONS
Bleeding and hypotension in noncardiac surgery are common and have a substantial impact on patient prognosis. The POISE-3 trial will evaluate two interventions to determine their impact on bleeding, cardiovascular complications, and mortality.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT03505723. Registered on 23 April 2018.
Identifiants
pubmed: 35101083
doi: 10.1186/s13063-021-05992-1
pii: 10.1186/s13063-021-05992-1
pmc: PMC8805242
doi:
Substances chimiques
Antifibrinolytic Agents
0
Tranexamic Acid
6T84R30KC1
Banques de données
ClinicalTrials.gov
['NCT03505723']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
101Subventions
Organisme : CIHR
ID : FDN-143302
Pays : Canada
Organisme : Research Grant Council, Hong Kong SAR
ID : 14104419
Organisme : National Health and Medical Research Council, Australia
ID : 1162362
Informations de copyright
© 2022. The Author(s).
Références
JAMA. 2017 Oct 10;318(14):1346-1357
pubmed: 28973220
Lancet. 2010 Jul 3;376(9734):23-32
pubmed: 20554319
Anesthesiology. 1994 Aug;81(2):299-307
pubmed: 8053578
Anesth Analg. 2018 Jun;126(6):1936-1945
pubmed: 29077608
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Knee Surg Sports Traumatol Arthrosc. 2012 Sep;20(9):1742-52
pubmed: 22065294
Pilot Feasibility Stud. 2020 Jul 21;6:104
pubmed: 32699643
Circulation. 2012 Jul 10;126(2):207-12
pubmed: 22679143
BMJ. 2012 May 17;344:e3054
pubmed: 22611164
Ann Intern Med. 2011 Apr 19;154(8):523-8
pubmed: 21502650
Anesthesiology. 2017 Jan;126(1):16-27
pubmed: 27775997
Lancet. 2020 Jun 20;395(10241):1927-1936
pubmed: 32563378
J Bone Joint Surg Br. 2011 Jan;93(1):39-46
pubmed: 21196541
JAMA. 2014 Dec 3;312(21):2254-64
pubmed: 25399007
Anesthesiology. 2017 Jan;126(1):47-65
pubmed: 27792044
CMAJ. 2019 Jul 29;191(30):E830-E837
pubmed: 31358597
Lancet. 2017 May 27;389(10084):2105-2116
pubmed: 28456509
Thromb Res. 2009 Mar;123(5):687-96
pubmed: 19007970
Ann Surg. 1990 Nov;212(5):567-80
pubmed: 2241312
BJS Open. 2021 Mar 5;5(2):
pubmed: 33839754
Br J Anaesth. 2017 Jul 1;119(1):174
pubmed: 28974084
N Engl J Med. 2017 Jan 12;376(2):136-148
pubmed: 27774838
Anesth Analg. 2002 Aug;95(2):273-7, table of contents
pubmed: 12145033
Eur J Orthop Surg Traumatol. 2015 Apr;25(3):525-41
pubmed: 25430635
JAMA. 2012 Dec 26;308(24):2594-604
pubmed: 23268518
Eur Spine J. 2013 Sep;22(9):1950-7
pubmed: 23657623
J Clin Anesth. 2017 Dec;43:77-83
pubmed: 29055803
JAMA Surg. 2021 Apr 14;:e210884
pubmed: 33851983
N Engl J Med. 2014 Apr 17;370(16):1494-503
pubmed: 24679062
Anesthesiology. 2013 Sep;119(3):507-15
pubmed: 23835589
BMJ. 2010 Mar 30;340:c117
pubmed: 20354011
JAMA. 2017 Apr 25;317(16):1642-1651
pubmed: 28444280
Anesthesiology. 2015 Jul;123(1):79-91
pubmed: 25929547
Anaesthesia. 1997 Feb;52(2):107-11
pubmed: 9059090
Anesth Analg. 2001 Jan;92(1):26-30
pubmed: 11133595
CMAJ. 2020 Aug 10;192(32):E901-E906
pubmed: 32778601
Lancet. 2008 May 31;371(9627):1839-47
pubmed: 18479744
Br J Anaesth. 2021 Jan;126(1):163-171
pubmed: 32768179
N Engl J Med. 2014 Apr 17;370(16):1504-13
pubmed: 24679061
Anaesthesist. 2007 Jun;56(6):557-61
pubmed: 17435976
JAMA. 2012 Jun 6;307(21):2295-304
pubmed: 22706835